|
|
Volumn 4, Issue 3, 2007, Pages 161-162
|
|
Learning from tesaglitazar
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2,4 THIAZOLIDINEDIONE DERIVATIVE;
CREATININE;
CYTOKINE;
FIBRINOGEN;
GLITAZONE DERIVATIVE;
HIGH DENSITY LIPOPROTEIN CHOLESTEROL;
INSULIN;
MURAGLITAZAR;
ORAL ANTIDIABETIC AGENT;
PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST;
PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST;
PLASMINOGEN ACTIVATOR INHIBITOR;
TESAGLITAZAR;
BINDING AFFINITY;
CLINICAL PRACTICE;
CLINICAL TRIAL;
DISEASE ASSOCIATION;
DISEASE COURSE;
DNA POLYMORPHISM;
DOSE RESPONSE;
DRUG ANTAGONISM;
DRUG EFFICACY;
DRUG FATALITY;
DRUG INFORMATION;
DRUG SAFETY;
DYSLIPIDEMIA;
EDEMA;
EDITORIAL;
GLOMERULUS FILTRATION;
GLUCOSE INTOLERANCE;
HEALTH PROGRAM;
HEART FAILURE;
HEMATOCRIT;
HUMAN;
HYPERGLYCEMIA;
HYPERTRIGLYCERIDEMIA;
INCIDENCE;
INSULIN RESISTANCE;
LEARNING;
LIPID STORAGE;
MEDICAL RESEARCH;
METABOLIC DISORDER;
MONOTHERAPY;
NON INSULIN DEPENDENT DIABETES MELLITUS;
RISK FACTOR;
SIDE EFFECT;
THROMBOSIS;
UNSPECIFIED SIDE EFFECT;
WEIGHT GAIN;
ALKANESULFONATES;
DIABETES MELLITUS, TYPE 2;
HUMANS;
MODELS, BIOLOGICAL;
PHENYLPROPIONATES;
PPAR ALPHA;
PPAR GAMMA;
|
|
EID: 34948897425
PISSN: 14791641
EISSN: None
Source Type: Journal
DOI: 10.3132/dvdr.2007.036 Document Type: Editorial |
|
Times cited : (11)
|
|
References (5)
|
